212 related articles for article (PubMed ID: 38331925)
1. Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis.
Khargekar N; Banerjee A; Athalye S; Mahajan N; Kargutkar N; Tapase P; Madkaikar M
Syst Rev; 2024 Feb; 13(1):60. PubMed ID: 38331925
[TBL] [Abstract][Full Text] [Related]
2. Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
[TBL] [Abstract][Full Text] [Related]
3. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
[TBL] [Abstract][Full Text] [Related]
4. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
[TBL] [Abstract][Full Text] [Related]
5. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N
Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
[TBL] [Abstract][Full Text] [Related]
7. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
[TBL] [Abstract][Full Text] [Related]
8. The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis.
Hasson C; Veling L; Rico J; Mhaskar R
Medicine (Baltimore); 2019 Dec; 98(51):e18225. PubMed ID: 31860969
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease.
Laurin LP; Nachman PH; Desai PC; Ataga KI; Derebail VK
Nephrol Dial Transplant; 2014 Jun; 29(6):1211-8. PubMed ID: 24084325
[TBL] [Abstract][Full Text] [Related]
10. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
[TBL] [Abstract][Full Text] [Related]
11. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
[TBL] [Abstract][Full Text] [Related]
12. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.
Ghafuri DL; Chaturvedi S; Rodeghier M; Stimpson SJ; McClain B; Byrd J; DeBaun MR
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035747
[TBL] [Abstract][Full Text] [Related]
13. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
[TBL] [Abstract][Full Text] [Related]
16. [Effect of hydroxyurea on hemoglobin S].
Torres AF; Eberle SE; Sciuccati G; Bonduel M
Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
[TBL] [Abstract][Full Text] [Related]
17. [Sickle cell anemia in children: value of hydroxyurea in severe forms].
Oury AP; Hoyoux C; Dresse MF; Chantraine JM
Arch Pediatr; 1997 Sep; 4(9):839-44. PubMed ID: 9345564
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Rankine-Mullings AE; Nevitt SJ
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
[TBL] [Abstract][Full Text] [Related]
19. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Wang WC; Dwan K
Cochrane Database Syst Rev; 2013 Nov; (11):CD003146. PubMed ID: 24226646
[TBL] [Abstract][Full Text] [Related]
20. Chronic organ injuries in children with sickle cell disease.
Allali S; Taylor M; Brice J; de Montalembert M
Haematologica; 2021 Jun; 106(6):1535-1544. PubMed ID: 33626864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]